• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Chugai Pharmaceutical Co., Ltd.

Monday, June 03, 2024
CP
Multiple Therapeutics
Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at https://www.chugai-pharm.co.jp/english/
Chugai Pharmaceutical Co., Ltd.
Company Website: https://www.chugai-pharm.co.jp/english
Lead Product in Development: GYM329: Anti-latent myostatin sweeping antibody AMY109: Anti-IL-8 recycling antibody NXT007: Anti-coagulation factor Ixa/X bispecific antibody LUNA18: RAS inhibitor, Mid-size molecule ERY974: Anti-Glypican-3/CD3 bispecific antibody STA551: Anti-CD137 agonistic Switch antibody SOF10: Anti-latent TGF-β1 monoclonal antibody ALPS12: Anti-DLL3/CD3/CD137 trispecific antibody SAIL66: AntiCLDN6/CD3/CD137 trispecific antibody ROSE12 SPYK04 DONQ52: Anti-HLA-DQ2.5/gluten peptides multispecific antibody RAY121 REVN24

Exchange

Tokyo

Ticker

4519

Company HQ City

Tokyo

Company HQ State

*

Company HQ Country

Japan

CEO/Top Company Official

Dr. Osamu Okuda, Representative Director, President & CEO

Development Phase of Primary Product

Multiple Products in Market
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS